Overall response in 29 patients with AML and high-risk MDS
Response . | No. (%) . |
|---|---|
| Complete response, CR | 7 (24) |
| First complete remission duration | |
| Less than 12 mo | 5 (23) |
| 12 mo or more | 2 (29) |
| Diagnosis | |
| AML | 7 (28) |
| MDS | 0* |
| Hematologic improvement, CRp | 5 (17) |
| AML | 3 (60) |
| MDS | 2 (40) |
| Overall response, CR and CRp | 12 (41) |
| Induction death, within 4 wk | 1 (3) |
| Resistance | 16 (55) |
Response . | No. (%) . |
|---|---|
| Complete response, CR | 7 (24) |
| First complete remission duration | |
| Less than 12 mo | 5 (23) |
| 12 mo or more | 2 (29) |
| Diagnosis | |
| AML | 7 (28) |
| MDS | 0* |
| Hematologic improvement, CRp | 5 (17) |
| AML | 3 (60) |
| MDS | 2 (40) |
| Overall response, CR and CRp | 12 (41) |
| Induction death, within 4 wk | 1 (3) |
| Resistance | 16 (55) |
Two of 4 patients with MDS achieved CRp.